Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes.
Recently a number of randomized trials have shown that patients with advanced colorectal cancer do not benefit from therapies targeting the epidermal growth factor receptor when their tumors harbor mutations in the KRAS, BRAF and PIK3CA genes. We developed two multiplex assays that simultaneously sc...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2010-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC2809099?pdf=render |
| _version_ | 1818059784433172480 |
|---|---|
| author | Irene Lurkin Robert Stoehr Carolyn D Hurst Angela A G van Tilborg Margaret A Knowles Arndt Hartmann Ellen C Zwarthoff |
| author_facet | Irene Lurkin Robert Stoehr Carolyn D Hurst Angela A G van Tilborg Margaret A Knowles Arndt Hartmann Ellen C Zwarthoff |
| author_sort | Irene Lurkin |
| collection | DOAJ |
| description | Recently a number of randomized trials have shown that patients with advanced colorectal cancer do not benefit from therapies targeting the epidermal growth factor receptor when their tumors harbor mutations in the KRAS, BRAF and PIK3CA genes. We developed two multiplex assays that simultaneously screen 22 nucleotides in the KRAS, NRAS, BRAF and PIK3CA genes for mutations. The assays were validated on 294 tumor DNA samples from patients with advanced colorectal cancer. In these samples 119 KRAS codon 12 and 13 mutations had been identified by sequence analysis, 126 tumors were wild-type for KRAS and the analysis failed in 49 of the 294 samples due to poor DNA quality. The two mutation assays detected 130 KRAS mutations, among which were 3 codon 61 mutations, and in addition 32 PIK3CA, 13 BRAF and 6 NRAS mutations. In 19 tumors a KRAS mutation was found together with a mutation in the PIK3CA gene. One tumor was mutant for both PIK3CA and BRAF. In summary, the mutations assays identified 161 tumors with a mutation, 120 were wild-type and the analysis failed in 13. The material cost of the 2 mutation assays was calculated to be 8-fold lower than the cost of sequencing required to obtain the same data. In addition, the mutation assays are less labor intensive. We conclude that the performance of the two multiplex mutation assays was superior to direct sequencing. In addition, these assays are cheaper and easier to interpret. The assays may also be of use for selection of patients with other tumor types. |
| first_indexed | 2024-12-10T13:22:02Z |
| format | Article |
| id | doaj.art-91f956bfdc1a4e15a9b50300fdea0750 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-10T13:22:02Z |
| publishDate | 2010-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-91f956bfdc1a4e15a9b50300fdea07502022-12-22T01:47:19ZengPublic Library of Science (PLoS)PLoS ONE1932-62032010-01-0151e880210.1371/journal.pone.0008802Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes.Irene LurkinRobert StoehrCarolyn D HurstAngela A G van TilborgMargaret A KnowlesArndt HartmannEllen C ZwarthoffRecently a number of randomized trials have shown that patients with advanced colorectal cancer do not benefit from therapies targeting the epidermal growth factor receptor when their tumors harbor mutations in the KRAS, BRAF and PIK3CA genes. We developed two multiplex assays that simultaneously screen 22 nucleotides in the KRAS, NRAS, BRAF and PIK3CA genes for mutations. The assays were validated on 294 tumor DNA samples from patients with advanced colorectal cancer. In these samples 119 KRAS codon 12 and 13 mutations had been identified by sequence analysis, 126 tumors were wild-type for KRAS and the analysis failed in 49 of the 294 samples due to poor DNA quality. The two mutation assays detected 130 KRAS mutations, among which were 3 codon 61 mutations, and in addition 32 PIK3CA, 13 BRAF and 6 NRAS mutations. In 19 tumors a KRAS mutation was found together with a mutation in the PIK3CA gene. One tumor was mutant for both PIK3CA and BRAF. In summary, the mutations assays identified 161 tumors with a mutation, 120 were wild-type and the analysis failed in 13. The material cost of the 2 mutation assays was calculated to be 8-fold lower than the cost of sequencing required to obtain the same data. In addition, the mutation assays are less labor intensive. We conclude that the performance of the two multiplex mutation assays was superior to direct sequencing. In addition, these assays are cheaper and easier to interpret. The assays may also be of use for selection of patients with other tumor types.http://europepmc.org/articles/PMC2809099?pdf=render |
| spellingShingle | Irene Lurkin Robert Stoehr Carolyn D Hurst Angela A G van Tilborg Margaret A Knowles Arndt Hartmann Ellen C Zwarthoff Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes. PLoS ONE |
| title | Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes. |
| title_full | Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes. |
| title_fullStr | Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes. |
| title_full_unstemmed | Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes. |
| title_short | Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes. |
| title_sort | two multiplex assays that simultaneously identify 22 possible mutation sites in the kras braf nras and pik3ca genes |
| url | http://europepmc.org/articles/PMC2809099?pdf=render |
| work_keys_str_mv | AT irenelurkin twomultiplexassaysthatsimultaneouslyidentify22possiblemutationsitesinthekrasbrafnrasandpik3cagenes AT robertstoehr twomultiplexassaysthatsimultaneouslyidentify22possiblemutationsitesinthekrasbrafnrasandpik3cagenes AT carolyndhurst twomultiplexassaysthatsimultaneouslyidentify22possiblemutationsitesinthekrasbrafnrasandpik3cagenes AT angelaagvantilborg twomultiplexassaysthatsimultaneouslyidentify22possiblemutationsitesinthekrasbrafnrasandpik3cagenes AT margaretaknowles twomultiplexassaysthatsimultaneouslyidentify22possiblemutationsitesinthekrasbrafnrasandpik3cagenes AT arndthartmann twomultiplexassaysthatsimultaneouslyidentify22possiblemutationsitesinthekrasbrafnrasandpik3cagenes AT ellenczwarthoff twomultiplexassaysthatsimultaneouslyidentify22possiblemutationsitesinthekrasbrafnrasandpik3cagenes |